clinical trial

August 30, 2016August 30, 2016

Adcetris May Improve or Cure Certain Hodgkin’s Lymphoma Patients After Failed Bone Marrow Transplant, Study Shows

News

Patients with Hodgkin’s lymphoma who failed to respond to autologous hematopoietic stem cell transplant (HSCT) may markedly benefit from Adcetris (brentuximab vedotin), according to end-of-study results of a Phase 2 ... Read more

August 29, 2016August 29, 2016

Opdivo Shows Potential in Specific Hodgkin’s Lymphoma Patients Whose Disease Progressed After Bone Marrow Transplant

News

Patients with classical Hodgkin’s lymphoma who progressed after receiving autologous hematopoietic stem cell transplant (HSCT) and treatment with Adcetris (brentuximab vedotin) may benefit from the PD-1 inhibitor Opdivo (nivolumab), according ... Read more

July 20, 2016July 20, 2016

Five-Year Trial Results Show Efficacy of Adcetris in Treating Hodgkin’s Lymphoma

News

Seattle Genetics and Takeda Pharmaceutical announced the publication of long-term, final results from the pivotal Phase 2 clinical trial that led to the approval of Adcetris (brentuximab vedotin) as monotherapy in patients with relapsed ... Read more

July 14, 2016July 14, 2016

Mantle Cell Lymphoma Patients Seen to Benefit by Adding Cytarabine to Stem Cell Transplant Chemotherapies

News

Immunochemotherapy with high-dose cytarabine followed by autologous hematopoietic stem cell transplant (ASCT) should be considered the standard of care for people with mantle cell lymphoma ages 65 or younger, according to the ... Read more

June 22, 2016June 22, 2016

Epizyme Presents Positive Clinical Data on Tazemetostat in Relapsed or Refractory Non-Hodgkin’s Lymphoma

News

Epizyme announced new and positive data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of orally administered tazemetostat in relapsed or refractory patients with non-Hodgkin’s lymphoma. The ... Read more

June 17, 2016June 17, 2016

EU Approves Gazyvaro (obinutuzumab) as a Treatment for Advanced Follicular Lymphoma

News

Roche announced that the European Commission has approved Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy, to treat follicular lymphoma patients who have failed to respond to, or whose disease progressed despite, treatment with rituximab (MabThera) or a ... Read more

May 27, 2016August 23, 2016

New Immunotherapy for Stem Cell Transplant to be Introduced at Biotechnology Convention

News

Xenikos B.V. will discuss its lead product candidate T-Guard, designed for acute graft versus host disease (GVHD), at the BIO International Convention 2016, June 6-9, in San Francisco, Calif. Transplantation of allogenic (donor-derived) ... Read more

May 25, 2016May 25, 2016

Idelalisib for Indolent Non-Hodgkin Lymphoma a Viable Option, Review Finds

News

In a comprehensive review of idelalisib (Zydelig) treatment for patients with indolent non-Hodgkin lymphoma, Hofstra University’s Jacqueline C Barrientos concluded that the drug is a promising option in patients who have already been ... Read more